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High blood pressure, sepsis, and snake bites might 
all be cured by the same antidote, according to 
Schneider et al. (page 2629).
High blood pressure and septic shock are both 
enhanced by a 21–amino acid peptide called ET-1. 
This peptide is secreted by blood vessel cells that 
have been activated by inflammatory cytokines. 
ET-1 triggers the contraction of smooth muscle 
cells that are wrapped around blood vessels, 
causing blood to flow through the squeezed 
vessels at a higher pressure. This contraction 
prevents blood from getting to its target tissues, 
leading to sepsis-associated organ malfunction.
ET-1 is structurally similar to a snake venom 
toxin called sarafotoxin. This toxin is lethal to 
mice that lack a type of immune cell called mast 
cells. These mice also die when sepsis-causing 
bacteria enter the abdominal cavity from an 
injured gut.
How mast cells protect against sepsis and 
snake venom, however, was unclear. They express 
both ET-1 receptors and 
degradative enzymes that 
normally destroy pathogens. 
The authors thus imagined 
that the mast cells might 
trap ET-1 (and the toxin) and 
then degrade it. They focused 
on mast cells’ most abundant 
defensive protease, Mc-cpa.
The team now shows 
that Mc-cpa is indeed the 
weapon of choice against ET-1 
and the toxin. Mice that lack mast cells died 
within hours after injection with ET-1. Mc-cpa 
protected mice by snipping and thus disarming the 
dangerous peptides. Mice that secreted inactive 
Mc-cpa were as susceptible to sepsis and snake 
venom as mice that lacked mast cells.
ET-1 is needed for mast cell activation, but its 
subsequent degradation might limit its long-term 
destructive effects. 
The use of DNA vaccines in humans 
has been limited by their relatively 
poor ability to build immunity 
against pathogens all on their own. 
Kwissa et al. (page 2733) now find 
that coinjecting a DNA vaccine with 
a Toll-like receptor (TLR) ligand 
activates dendritic cells (DCs) and 
goads monkeys into putting up a 
better fight against SIV.
Because they are cheaper and easier 
to manufacture than recombinant pro-
tein vaccines, successful DNA vaccines 
are in high demand. So far, however, 
DNA vaccines targeted against malaria, 
hepatitis B, and HIV have failed to 
induce a strong immune response in 
either monkeys or humans.
For various other types of vac-
cines, TLR ligands are commonly 
coinjected to improve the patient’s immune response. The 
ligands activate DCs, which in turn secrete immune-boosting 
cytokines and enhance the proliferation and activity of T 
cells. Despite their success in protein vaccines, TLR ligands 
have not been tested as supplements to DNA vaccines in 
humans or other primates.
Findings from Kwissa et al. now suggest that TLR ligands 
may indeed make human DNA vaccines more effective. The 
authors report that monkeys are better at fighting off SIV 
infection if their DCs are also activated by a TLR ligand at the 
time of DNA vaccination. The ligand of choice was TLR-9, 
which is primarily expressed by a subset of DCs known to 
boost the numbers of antiviral CD8+ T cells.
This dual injection increased the total numbers of SIV-
specific T cells. Many of these cells secreted a broader range 
of protective cytokines than did T cells from monkeys given 
only the DNA vaccine. However, the mechanism by which 
the TLR-9–activated DCs instruct T cells to secrete more 
types of cytokines is unclear.
In humans, survival from HIV infection is correlated 
with the numbers of CD4+ T cells—particularly the 
precursors of virus-fighting effector cells—in the gut. 
These precursors were more abundant a few weeks after 
SIV infection in monkeys that were given the coinjection 
regimen. Whether this stronger protection is also long 
lasting remains to be tested. 
Without the mast cell protease Mc-cpa, most mice 
die within an hour of being injected with ET-1.
SIV loads are lower 
in monkeys given 
both a DNA vaccine 
and a DC-activating 
TLR ligand (red).
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